ISRCTN95053737
Completed
Not Applicable
A prospective randomized study of adjuvant chemotherapy with navelbine and cisplatin in completely resected non small cell lung cancer
Pierre Fabre Oncologie (France)0 sites840 target enrollmentMarch 22, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Pierre Fabre Oncologie (France)
- Enrollment
- 840
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically proven primary non small cell lung cancer (NSCLC) (except bronchoalveolar carcinoma) stage I (T2N0 only), II, and IIIA according to the 1986 TNM classification
- •2\. Complete resection of the primary tumor (all margins free of disease)
- •3\. Age 18\-75 years
- •4\. World Health Organization (WHO) performance status \=2
- •5\. Adequate biological functions
Exclusion Criteria
- •1\. Patients with a history of concurrent malignancy (except adequately treated non\-melanoma skin cancer or in situ cervical cancer)
- •2\. Previous treatment with adjuvant therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervixCervix cancerCancerMalignant neoplasm of cervix uteriISRCTN52711596Cancer Research UK (CRUK) (UK)
Active, not recruiting
Not Applicable
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-ESEncore Clinical, Inc1,050
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-FRIFCT1,050
Recruiting
Phase 1
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lungcancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code: 10025050Term: Lung cancer non-small cell stage I Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025051Term: Lung cancer non-small cell stage II Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025044Term: Lung cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511185-37-00Razor Genomics Inc.915
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-DERazor Genomics, Inc.1,050